Acetylon Pharmaceuticals to Present at UBS Global Healthcare Conference
5/20/2013 7:17:25 AM
More...
|
Clinical and Preclinical Results for Acetylon Pharmaceuticals' ACY-1215 for the Treatment of Multiple Myeloma Presented at the 54th Annual Meeting of the American Society of Hematology
12/11/2012 10:26:26 AM
More...
|
Preclinical Results for Acetylon Pharmaceuticals' Selective HDAC1/2 Inhibitor for the Treatment of Sickle Cell Disease and Beta-Thalassemia Presented at American Society of Hematology 2012
12/11/2012 9:44:43 AM
More...
|
Acetylon Pharmaceuticals' Selective HDAC Inhibitor Programs to be Featured at the 54th Annual Meeting of the American Society of Hematology
11/20/2012 9:48:55 AM
More...
|
Acetylon Pharmaceuticals to Participate on Financing Panel and Provide Corporate Update at Biotechnology Industry Organization (BIO) Investor Forum
10/9/2012 9:34:17 AM
More...
|
Acetylon Pharmaceuticals to Participate in Upcoming Conferences
9/10/2012 9:27:36 AM
More...
|
Acetylon Pharmaceuticals Initiates New Phase 1b Clinical Trial of Rocilinostat (ACY-1215) in Combination with Celgene Corporation (CELG)'s Revlimid® (Lenalidomide) and Dexamethasone for Patients with Multiple Myeloma
8/1/2012 10:23:58 AM
More...
|
Acetylon Pharmaceuticals Announces Issuance of a United States Patent with Composition of Matter Claims for Its Lead HDAC6 Inhibitor Drug Candidate ACY-1215
4/20/2012 10:43:25 AM
More...
|
Celgene (CELG) Pours $15 Million Into Acetylon Pharmaceuticals, Takes "Observer" Role on Board
2/9/2012 6:57:10 AM
More...
|
Acetylon Pharmaceuticals Announces Publication of Preclinical Pharmacokinetic, Pharmacodynamic and Bone Disease Results for ACY-1215 in Multiple Myeloma
12/12/2011 7:29:51 AM
More...
|
|